PARP1 and neoplasm: Our strategy of tumor-targeted delivery of chemotherapy, followed by the sequential administration of a DDR inhibitor (Fig. 1), allowed dose escalation of both the PARP inhibitor and TOP1 inhibitor to approximately 80% of their respective single-agent MTDs.